Cargando…

Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study

OBJECTIVE: To evaluate the efficacy and safety of etanercept (ETN) after 48 weeks in patients with early active non-radiographic axial spondyloarthritis (nr-axSpA). METHODS: Patients meeting Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axSpA, but not modif...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maksymowych, Walter P, Dougados, Maxime, van der Heijde, Désirée, Sieper, Joachim, Braun, Jürgen, Citera, Gustavo, Van den Bosch, Filip, Logeart, Isabelle, Wajdula, Joseph, Jones, Heather, Marshall, Lisa, Bonin, Randi, Pedersen, Ron, Vlahos, Bonnie, Kotak, Sameer, Bukowski, Jack F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941178/ https://www.ncbi.nlm.nih.gov/pubmed/26269397 http://dx.doi.org/10.1136/annrheumdis-2015-207596

Ejemplares similares

Evaluation of the change in structural radiographic sacroiliac joint damage after 2 years of etanercept therapy (EMBARK trial) in comparison to a contemporary control cohort (DESIR cohort) in recent onset axial spondyloarthritis
por: Dougados, Maxime, et al.
Publicado: (2018)

Structural changes in the sacroiliac joint on MRI and relationship to ASDAS inactive disease in axial spondyloarthritis: a 2-year study comparing treatment with etanercept in EMBARK to a contemporary control cohort in DESIR
por: Maksymowych, Walter P., et al.
Publicado: (2021)

Modification of structural lesions on MRI of the sacroiliac joints by etanercept in the EMBARK trial: a 12-week randomised placebo-controlled trial in patients with non-radiographic axial spondyloarthritis
por: Maksymowych, Walter P, et al.
Publicado: (2018)

Relationship between disease activity status or clinical response and patient-reported outcomes in patients with non-radiographic axial spondyloarthritis: 104-week results from the randomized controlled EMBARK study
por: Dougados, Maxime, et al.
Publicado: (2020)

Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)
por: Sieper, Joachim, et al.
Publicado: (2013)

Etanercept in axial spondyloarthritis
por: Luo, Gui, et al.
Publicado: (2022)

Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis
por: López-Medina, Clementina, et al.
Publicado: (2019)

Spinal Inflammation in the Absence of Sacroiliac Joint Inflammation on Magnetic Resonance Imaging in Patients With Active Nonradiographic Axial Spondyloarthritis
por: van der Heijde, Désirée, et al.
Publicado: (2014)

Is a positive family history of spondyloarthritis relevant for diagnosing axial spondyloarthritis once HLA-B27 status is known?
por: van Lunteren, Miranda, et al.
Publicado: (2019)

Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study
por: Dougados, Maxime, et al.
Publicado: (2014)

A Randomized, Double‐Blind, Placebo‐Controlled, Sixteen‐Week Study of Subcutaneous Golimumab in Patients With Active Nonradiographic Axial Spondyloarthritis
por: Sieper, J., et al.
Publicado: (2015)

Effect of Certolizumab Pegol Over Ninety-Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial
por: Sieper, J, et al.
Publicado: (2015)

Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE
por: Landewé, Robert, et al.
Publicado: (2020)

Referral Patterns, Diagnosis, and Disease Management of Patients With Axial Spondyloarthritis: Results of an International Survey
por: van der Heijde, Désirée, et al.
Publicado: (2014)

Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial
por: van der Heijde, Désirée, et al.
Publicado: (2018)

Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA
por: van der Heijde, Désirée, et al.
Publicado: (2017)

MRI evidence of structural changes in the sacroiliac joints of patients with non-radiographic axial spondyloarthritis even in the absence of MRI inflammation
por: Maksymowych, Walter P., et al.
Publicado: (2017)

Evaluation of multiple referral strategies for axial spondyloarthritis in the SPondyloArthritis Caught Early (SPACE) cohort
por: Abawi, Ozair, et al.
Publicado: (2017)

Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial
por: Song, I-H, et al.
Publicado: (2011)

Imaging Outcomes for Axial Spondyloarthritis and Sensitivity to Change: A Five‐Year Analysis of the DESIR Cohort
por: Sepriano, Alexandre, et al.
Publicado: (2022)

Sustained clinical response and safety of etanercept in patients with early axial spondyloarthritis: 10-year results of the ESTHER trial
por: Proft, Fabian, et al.
Publicado: (2021)

Geographical prevalence of family history in patients with axial spondyloarthritis and its association with HLA-B27 in the ASAS-PerSpA study
por: Boel, Anne, et al.
Publicado: (2022)

Age at onset in axial spondyloarthritis around the world: data from the Assessment in SpondyloArthritis international Society Peripheral Involvement in Spondyloarthritis study
por: Boel, Anne, et al.
Publicado: (2021)

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
por: Dougados, Maxime, et al.
Publicado: (2020)

Spinal Radiographic Progression in Early Axial Spondyloarthritis: Five‐Year Results From the DESIR Cohort
por: Ramiro, Sofia, et al.
Publicado: (2019)

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study
por: Landewé, R, et al.
Publicado: (2014)

Sacroiliac radiographic progression in recent onset axial spondyloarthritis: the 5-year data of the DESIR cohort
por: Dougados, Maxime, et al.
Publicado: (2017)

5-year follow-up of spinal and sacroiliac MRI abnormalities in early axial spondyloarthritis: data from the DESIR cohort
por: Madari, Queeny, et al.
Publicado: (2020)

Inflammation of the Sacroiliac Joints and Spine and Structural Changes on Magnetic Resonance Imaging in Axial Spondyloarthritis: Five‐Year Data From the DESIR Cohort
por: Sepriano, Alexandre, et al.
Publicado: (2021)

Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction
por: Landewé, Robert BM, et al.
Publicado: (2020)

Uncovering the heterogeneity of disease impact in axial spondyloarthritis: bivariate trajectories of disease activity and quality of life
por: Imkamp, Maike, et al.
Publicado: (2018)

Tumor Necrosis Factor Inhibitors Reduce Spinal Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: A Longitudinal Analysis From the Alberta Prospective Cohort
por: Sepriano, Alexandre, et al.
Publicado: (2021)

Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis
por: Schoels, M M, et al.
Publicado: (2014)

Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis
por: Hebeisen, Monika, et al.
Publicado: (2019)

The Effect of Etanercept in Nonradiographic Axial Spondyloarthritis by Stratified C‐Reactive Protein Levels
por: Tam, Hoi Ki Joshua, et al.
Publicado: (2021)

Treatment of Axial Spondyloarthritis: What Does the Future Hold?
por: Poddubnyy, Denis, et al.
Publicado: (2020)

Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis
por: Rudwaleit, M., et al.
Publicado: (2016)

A Fifty‐Two–Week, Randomized, Placebo‐Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis
por: Deodhar, Atul, et al.
Publicado: (2019)

Biological DMARDs and disease modification in axial spondyloarthritis: a review through the lens of causal inference
por: Sepriano, Alexandre, et al.
Publicado: (2021)

Is the current ASAS expert definition of a positive family history useful in identifying axial spondyloarthritis? Results from the SPACE and DESIR cohorts
por: Ez-Zaitouni, Zineb, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_h40b7i6omobjdl8fk3u55r4lqg